Navigation Links
Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
Date:10/22/2007

PASADENA, Calif., Oct. 22 /PRNewswire/ -- Maven Biotechnologies, LLC, an early stage biotechnology company developing a label-free multiplexing immunodiagnostic analysis system, today announced that the company will deliver a presentation at the BIOCOM Investor Conference in San Diego, California. Jeffrey C. Travis, Ph.D., Maven's President and COO, will present on Thursday, November 1, 2007 at 3:30 PM.

About Maven Biotechnologies

Maven Biotechnologies, LLC has developed LFIRE(TM) (Label-Free Internal Reflection Ellipsometry) which is a complete diagnostics analysis system (instruments and disposables) that provides a next generation replacement measurement technology with significant cost benefits to the healthcare sector and technology improvements for the combined $15 B w/w immunodiagnostic markets. It offers the potential advantages of 50-75% reduced costs to both the diagnostics manufacturers and the clinical or pharma lab user. In addition, its breakthrough new way to measure immunodiagnostic tests more rapidly will positively impact point-of-care (POC) tests for emergency room screening (e.g. cardiac markers, drugs of abuse, etc.), at patient bedside, and in the O.R. Finally, it uniquely permits single to high density label-free multiplexing -- that is, when one to large numbers of tests per patient can be run at one time (e.g. tumor markers, autoimmune panels, etc.), greatly reducing costs for the patients, healthcare provider and importantly, the medical insurance industry. LFIRE(TM) is an enabling technology for more cost effective patient profiling of multiple tests for diagnosis, staging of disease and choice of targeted drug therapy, all key elements required for the medical industry's personalized medicine initiative. Most significantly, the market infrastructure for this technology already exists in the worldwide diagnostics and pharma industries and market penetration for this improved next generation, markedly cost effective, replacement measurement technology will be rapid. The Company is now planning development for the first commercial versions of LFIRE(TM), with planned market launch later in 2008.

http://www.mavenbiotech.com


'/>"/>
SOURCE Maven Biotechnologies, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Cambridge, MA (PRWEB) , ... January 20, 2017 ... ... and scientific consulting and resource to the healthcare industry ( http://www.gandlscientific.com ), has ... to its expanding team of clinical and scientific consultants and contractors. This is ...
(Date:1/21/2017)... , Jan. 20, 2017 Interpace ... a company that provides clinically useful molecular diagnostic ... has entered into a securities purchase agreement with ... 855,000 shares of common stock in a registered ... Company has agreed to sell to the same ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, today presented ... compound, napabucasin, at the 2017 American Society of Clinical ... Francisco . In a Phase ... agent designed to inhibit cancer stemness pathways by targeting ...
(Date:1/20/2017)... 20, 2017 Ginkgo Bioworks, the organism ... pioneer in the synthesis and assembly of DNA. ... assembling pathway-length synthetic DNA into Ginkgo,s automated organism ... the construction of new organism designs for application ... "Gen9 was founded to significantly increase the world,s ...
Breaking Biology Technology:
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
Breaking Biology News(10 mins):